Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Thromb Haemost 1997; 77(05): 1040-1041
DOI: 10.1055/s-0038-1656104
DOI: 10.1055/s-0038-1656104
Letter to the Editor
Characterisation of Fibrinogen Oslo IV by Electrospray Mass Spectrometry
Authors
Further Information
Publication History
Received 30 October 1996
Accepted after revision 07 January 1997
Publication Date:
11 July 2018 (online)
-
References
- 1 Stormorken H, Brosstad F, Seim H. A new dysfibrinogenemia: Fibrinogen Oslo IV. Thromb Haemost 1983; 49: 120-122
- 2 Brennan SO, Hammonds B, George PM. Aberrant hepatic processing causes removal of activation peptide and primary polymerisation stie from fibrinogen Canterbury (Aα 20→Val Asp). J Clin Invest 1995; 96: 2854-2858
- 3 Blombäck B, Hessel B, Fields R, Procyk R. Fibrinogen Aarhus: An abnormal fibrinogen with Aα19 Arg→Gly substitution. In: Fibrinogen 3: Biochemical and Biological Function, Gene Regulation and Expression. Mosesson MW, Amrani DL, Siebenlist KR, Di Orio JP. eds. Elsevier Scientific Publishers BV. 1988: 263-266
- 4 Dempfle C-EH, Henschen A. Fibrinogen Mannheim I: Identification of an Aα19→ArgGly substitution in dysfibrinogenaemia associated with bleeding tendency. In: Fibrinogen 4: Current Issues and Clinical Aspects. Matsuda M, Iwanga S, Takada A, Henschen A. eds. Elsevier Scientific Publishers BV. 1990: 159-165
- 5 Yamaguchi FI, Sugo T, Hashimoto Y, Kimura K, Okajima K, Matsuda M. Fibriogen Kumamoto with an A α 19→Gly substitution associated clinically with thrombosis. Fibrinolysis 1996; 10 (Suppl. 04) 23